1. Search Result
Search Result
Results for "

PD I

" in MedChemExpress (MCE) Product Catalog:

23

Inhibitors & Agonists

2

Peptides

4

Inhibitory Antibodies

2

Recombinant Proteins

2

Antibodies

7

Oligonucleotides

Targets Recommended:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-124700
    LYPLAL1-IN-1
    1 Publications Verification

    Cyclic GMP-AMP Synthase STING PD-1/PD-L1 Epoxide Hydrolase Metabolic Disease
    LYPLAL1-IN-1 (compound 11) is a selective, covalent, and irreversible inhibitor of the lysophospholipase-like enzyme LYPLAL1 (IC50 = 6 nM). LYPLAL1-IN-1 shows selectivity against other serine hydrolases such as carboxylesterase CES1 (IC50 > 50 μM for CES1). LYPLAL1-IN-1 inhibits the depalmitoylation function of LYPLAL1, blocking its depalmitoylation modification of cyclic GMP-AMP synthase (cGAS), thereby promoting cGAS dimerization and activation, and initiating the cGAS-STING pathway-mediated innate immune response. LYPLAL1-IN-1 can enhance DNA-induced type I interferon production, upregulate PD-L1 expression in tumor cells, and promote the accumulation of tumor-infiltrating CD8 + T cells, with the core function of strengthening the anti-tumor immune response. LYPLAL1-IN-1 is primarily used in tumor immunology research, especially in combination with PD-1/PD-L1 inhibitors .
    LYPLAL1-IN-1
  • HY-153598

    PROTACs RIP kinase Apoptosis Inflammation/Immunology Cancer
    LD4172 is a selective RIPK1 PROTAC degrader with a Ki of 4.8 nM. LD4172 induces RIPK1 protein degradation via ternary complex formation with RIPK1 and VHL E3 ligase, driving ubiquitination and proteasomal breakdown. LD4172 abrogates TNF-induced classical NF-κB signaling in TRAF2-deficient cells, impairing IκBα phosphorylation and degradation, and reducing IL-8 production. LD4172 induces apoptosis and immunogenic cell death in tumor cells, enhances tumor-infiltrating lymphocyte responses, and sensitizes tumors to anti-PD1 therapy. LD4172 acts as a chemical probe for investigating RIPK1 scaffolding functions. LD4172 can be used for the research of melanoma, colon cancer .
    LD4172
  • HY-155457

    Phosphodiesterase (PDE) STING Cancer
    Enpp-1-IN-19 (compound 29f) is an orally active ENPP1 inhibitor that inhibits cGAMP hydrolysis by ENPP1 (IC50=68 nM). Enpp-1-IN-19 increases anti-PD-L1 responses and inhibits tumor growth in CT26 syngeneic models. Enpp-1-IN-19 also enhances STING-mediated type I interferon responses, induces immune memory, and prevents tumor recurrence .
    Enpp-1-IN-19
  • HY-156871

    CaMK Cancer
    CAMK1D-IN-1 (compound I) is an inhibitor of CAMK1D, targeting cytotoxic T lymphocyte (CTL)-resistant tumor cells. CAMK1D impairs CTL-induced death receptor signaling and apoptosis by inhibiting caspases, making it a key and effective target for PD-L1-refractory tumors .
    CAMK1D-IN-1
  • HY-RS10265

    Small Interfering RNA (siRNA) Others

    PDIA2 Human Pre-designed siRNA Set A contains three designed siRNAs for PDIA2 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

    PDIA2 Human Pre-designed siRNA Set A
    PDIA2 Human Pre-designed siRNA Set A
  • HY-RS18780

    Small Interfering RNA (siRNA) Others

    P4hb Mouse Pre-designed siRNA Set A contains three designed siRNAs for P4hb gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.

    P4hb Mouse Pre-designed siRNA Set A
    P4hb Mouse Pre-designed siRNA Set A
  • HY-P4569

    Dipeptidyl Peptidase Others
    H-Ser-Pro-OH is a dipeptide containing serine and proline, which can serve as a substrate for prolinase I (PD I) and PD II. H-Ser-Pro-OH can also be used for the synthesis of polypeptide .
    H-Ser-Pro-OH
  • HY-RS09945

    Small Interfering RNA (siRNA) Others

    P4HB Human Pre-designed siRNA Set A contains three designed siRNAs for P4HB gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

    P4HB Human Pre-designed siRNA Set A
    P4HB Human Pre-designed siRNA Set A
  • HY-146260

    PI3K Cancer
    NVP-CLR457 (compound 40) is an orally active, potent and balanced pan-class I PI3K inhibitor. NVP-CLR457 shows a clear dose-dependent PK/PD/efficacy relationship. NVP-CLR457 has antitumor activity .
    NVP-CLR457
  • HY-P2474

    PD-1/PD-L1 Cancer
    Human PD-L1 inhibitor I is a hPD-1 peptide ligand, with a KD of 3.39 μM. Human PD-L1 inhibitor I may disturb the binding of hPD-L1 to hPD-1 .
    Human PD-L1 inhibitor I
  • HY-P99619

    SCT-I10A

    PD-1/PD-L1 Cancer
    Finotonlimab (SCT-I10A) is a recombinant humanised IgG PD-1 antibody. Finotonlimab has the potential for solid tumors or lymphomas research .
    Finotonlimab
  • HY-162972

    PROTACs PD-1/PD-L1 Cancer
    PROTAC PD-L1 degrader-2 (Compound 9i) is a PROTAC degrader for PD-L1, that inhibits PD-L1 with an IC50 of 197.4 nM and exhibits an affinity with PD-L1 with a Kd of 301 nM. PROTAC PD-L1 degrader-2 promotes the internalization of PD-L1 on the cell membrane, and induces PD-L1 degradation via the synergistic effect of the proteasome and lysosomal pathways. PROTAC PD-L1 degrader-2 can activate the immune system, and exhibits antitumor efficacy in MC38 C57BL/6 mouse model .
    PROTAC PD-L1 degrader-2
  • HY-P990251

    MMP Collagen PD-1/PD-L1 Inflammation/Immunology Cancer
    Anti-Human/Mouse denatured collagen type-I Antibody (XL313) is a mouse-derived IgG1 κ type antibody inhibitor, targeting to human/mouse denatured collagen type-I. Anti-Human/Mouse denatured collagen type-I Antibody (XL313) selectively binds to proteolyzed collagen type I. Anti-Human/Mouse denatured collagen type-I Antibody (XL313) reduces PD L1 levels in tumor cells. Anti-Human/Mouse denatured collagen type-I Antibody (XL313) can be used for the researches of cancer and inflammation, such as such as ovarian tumor .
    Anti-Human/Mouse denatured collagen type-I Antibody (XL313)
  • HY-112405

    PD 159121

    EGFR Cancer
    BPIQ-I (PD 159121) is a potent and ATP-competitive EGFR tyrosine kinase inhibitor.. BPIQ-I shows anti-proliferative actively .
    BPIQ-I
  • HY-RS09960

    Small Interfering RNA (siRNA) Others

    PADI1 Human Pre-designed siRNA Set A contains three designed siRNAs for PADI1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

    PADI1 Human Pre-designed siRNA Set A
    PADI1 Human Pre-designed siRNA Set A
  • HY-120238

    Angiotensin Receptor Cardiovascular Disease
    RG 13647 is an AT2-selective ligand. RG 13647 is an analog of PD 123177 (HY-121767). RG 13647 shows weak activity in competing for [125I]angiotensin II binding with an IC50 value of 100 μM. RG 13647 can be used for research of cardiovascular disease .
    RG 13647
  • HY-RS10267

    Small Interfering RNA (siRNA) Others

    Pdia3 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Pdia3 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.

    Pdia3 Mouse Pre-designed siRNA Set A
    Pdia3 Mouse Pre-designed siRNA Set A
  • HY-168491

    Phosphodiesterase (PDE) STING PD-1/PD-L1 Cancer
    Enpp-1-IN-25 (Compound 30) is an ENPP1 inhibitor with an IC50 of 8.05 nM and low oral bioavailability. Enpp-1-IN-25 can effectively activate the intracellular STING pathway by inhibiting cGAMP degradation. Enpp-1-IN-25 can enhance immune cell infiltration in the tumor microenvironment and type I interferon responses, and potentiate the antitumor efficacy of the anti-PD-L1 antibody. Enpp-1-IN-25 can be used in the research of cancer immunotherapy .
    Enpp-1-IN-25
  • HY-RS25269

    Small Interfering RNA (siRNA) Others

    P4hb Rat Pre-designed siRNA Set A contains three designed siRNAs for P4hb gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.

    P4hb Rat Pre-designed siRNA Set A
    P4hb Rat Pre-designed siRNA Set A
  • HY-P991847

    PD-1/PD-L1 Cancer
    Anti-PD-L2 Antibody (3.2) recognizes an epitope on mouse and human PD-L2. PD-L2 is a 25 kD type I transmembrane protein and a member of B7 family within the immunoglobulin receptor superfamily. Recommend Isotype Controls: Mouse IgG1 kappa, Isotype Control (HY-P99977) .
    Anti-PD-L2 Antibody (3.2)
  • HY-136785

    Endothelin Receptor Radionuclide-Drug Conjugates (RDCs) Cardiovascular Disease
    PD151242 is a selective competitive antagonist of the endothelin ETA receptor, with KD values of 0.65 nM, 0.64 nM and 1.92 nM for human, rat and porcine receptors, respectively, and a KD value of 104 μM for the human ETβ receptor. When radiolabeled as [ 125I]-PD151242, PD151242 can be used to visualize and localize renal vascular ETA receptors .
    PD151242
  • HY-RS18831

    Small Interfering RNA (siRNA) Others

    Padi2 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Padi2 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.

    Padi2 Mouse Pre-designed siRNA Set A
    Padi2 Mouse Pre-designed siRNA Set A
  • HY-P992353

    LILRB Cancer
    ES009 is a high-affinity LILRB2 antagonist, with IC50 values of 14.07 nM and 18.61 nM for inhibiting hLILRB2-huANGPTL3 and hLILRB2-huANGPTL4, respectively. ES009 specifically blocks the interactions between LILRB2 and MHC class I as well as non-MHC ligands, thereby effectively inhibiting receptor activation. ES009 can reprogram anti-inflammatory myeloid cells and induce their conversion to a pro-inflammatory phenotype, and also reverse the T cell suppression mediated by macrophages. When combined with anti-PD-1 blockade therapy, ES009 synergistically enhances T cell activation. ES009 can be used in research related to advanced solid tumors and ovarian cancer .
    ES009

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

 

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

 

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: